Introducing FDI, the Florey Dementia Index for Alzheimer's onset prediction
A predictive tool for determining the age at which individuals may develop mild cognitive impairment (MCI) or Alzheimer's ...
Rising Kashmir45m
Two Kashmiri ophthalmologists honoured at national level
Two Kashmiri ophthalmologists have been honored at national level at the 8th National Assembly of Forum of Ophthal Teachers ...
manilatimes7d
MCI Study: Brain Exercises Drive Cognitive and Functional Gains in Pre-Dementia Patients
This is the 29 th published study on the use of BrainHQ in patients with MCI or other forms of pre-dementia. Prior studies ...
HealthDay on MSN6d
Dementia index shows validity for predicting age of onset of MCI, Alzheimer’s disease
In a simulated trial, the Florey Dementia Index achieved mean absolute errors of 1.57 and 0.70 years for predicting mild cognitive impairment and Alzheimer's disease onset, respectively ...
Hosted on MSN2d
New Criteria Developed for Appropriate Use of Amyloid, Tau PET
Appropriate use criteria (AUC) for the use of amyloid and tau positron emission tomography (PET) have been issued by the ...
Healio11d
Alzheimer’s experts revise guidelines for amyloid, tau PET utilization
Revised guidelines for amyloid and tau positron emission tomography for Alzheimer’s disease and dementia state these tests ...
DelveInsight Business Research, LLP: Mild Cognitive Impairment Market is Predicted to Advance at a CAGR of 11.6% by 2034 | DelveInsight
According to DelveInsight's analysis, the mild cognitive impairment market is anticipated to increase during the forecast period (2024-2034), owing to the rise in the launch of emerging therapies ...
Medindia12d
Mild Cognitive Impairment Market is Predicted to Advance at a CAGR of 11.6% by 2034 | DelveInsight
Mild Cognitive Impairment Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the mild cognitive impairment ...
New criteria developed for appropriate use of cognitive impairment imaging tools
Appropriate use criteria (AUC) for the use of amyloid and tau positron emission tomography (PET) have been issued by the ...
FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has accepted BioArctic's partner Eisai's Biologics License Application (BLA) for Leqembi ...